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Background  and  purpose:  Coronary  collateral  circulation  (CCC)  has  been  demonstrated  to  be impaired
in  patients  with  type  2  diabetes  mellitus  which  is  characterized  by  insulin  resistance.  In  this  study,  our
purpose  was  to ﬁnd  out a possible  relationship  between  CCC  and  non-alcoholic  fatty  liver disease  (NAFLD),
which  is also  characterized  by  insulin  resistance,  in  non-diabetic  patients  with  severe  coronary  artery
disease.
Methods:  One  hundred  and  ﬁfty-one  consecutive  non-diabetic  patients  with  stable  angina  pectoris  who
were  found  to  have  >95%  stenosis  of at least  one  major  coronary  artery  were  enrolled.  Abdominal  ultra-
sonography  (USG)  was  performed  after  coronary  angiography  to  determine  the presence  or  absence  of
NAFLD.
Results:  According  to Cohen–Rentrop  method,  81  (53.7%)  patients  had  good  and  70 (46.3%)  patients  had
poor  collateral  development.  NAFLD  was  present  in 98  patients  (64.9%  of  study  population)  and  more
prevalent  in  patients  with  poor  collateral  development  [58  of  70 patients  (82.9%)  vs.  40 of 81  patients
(49.4%),  p  <  0.001].  Mean  Rentrop  collateral  score  was  signiﬁcantly  lower  in  patients  with  NAFLD  (1.2 ±  1.2
vs. 2.1  ± 0.9, p  < 0.001).  Shorter  angina  time,  metabolic  syndrome,  presence  of insulin  resistance,  less
severe coronary  artery  disease,  and  female  sex  were  also  associated  with  poor  collateral  development.
When  the logistic  regression  analysis  was performed  using  these  factors,  NAFLD  was still  signiﬁcantly
related  to  poor  collateral  development.
Conclusions:  Presence  of  NAFLD  is associated  with  poor  coronary  collateral  development  in  non-diabetic
patients  with  severe  coronary  artery  disease  independent  from  other  variables,  especially  metabolic
syndrome  and  insulin  resistance.  Which  mechanisms  play  role  in  this  association  is needed  to be  cleared
with  further  studies.
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. Introduction
Coronary collateral development improves survival by reducing
yocardial infarct size, ventricular aneurysm formation and future
ardiovascular events in patients with occlusive coronary lesions
1,2]. Collateral development may  be affected by several factors
uch as existence of diabetes mellitus (DM), severity of coronary
rtery disease, and duration of ischemic symptoms [3–5]. Pres-
nce of metabolic syndrome (MS) and associated insulin resistance
IR) have been also shown to be associated with poor collateral
evelopment [6–8], however there is a controversy about the asso-
iation between MS  and collateralization in the literature, since in
∗ Corresponding author at: Güvenlik Caddesi No. 38/4, A. Ayranci, Ankara, Turkey.
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914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.05.003anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
a study conducted by Olijhoek et al., presence of MS  did not impair
collateral development [9].
Non-alcoholic fatty liver disease (NAFLD) which is consid-
ered as a hepatic manifestation of MS  [10] has an increasing
prevalence in Western countries. NAFLD has been found to be
associated with increased risk for coronary artery disease (CAD)
independent of MS  and its components [11], but until now,
no study has been conducted to investigate the relationship
between NAFLD and coronary collateral circulation (CCC) which
is related to poor cardiovascular outcomes in patients with severe
CAD.
CCC may  be also impaired in patients with NAFLD which shares
IR as the common pathophysiological mechanism with type 2 DM,
whose presence is known to be associated with poor collateral
development [3,6–8].  With this in mind, our aim in this study was to
ﬁnd out a possible relationship between coronary collateral devel-
opment and NAFLD.
vier Ltd. All rights reserved.
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. Methods
Consecutive patients who were found to have >95% stenosis of
t least one major coronary artery in their ﬁrst coronary angiogram
ere enrolled in the study. Informed consent was  obtained from
ll participants and the study protocol was approved by the local
thics Committee. The exclusion criteria included known CAD, pre-
ious percutaneous or surgical revascularization history, and acute
oronary syndrome either with or without ST elevation in the last
 month. Diabetic patients were not included because DM is the
est known disease associated with poor collateral development
3]; so that potential detrimental effects of DM on collateral devel-
pment could be eliminated. DM was deﬁned as plasma fasting
lucose ≥126 mg/dl and/or the current use of diabetes medication.
Chronic alcohol consumption (>20 g/day), serum hepatitis B
ntigen or anti-hepatitis C antibody positivity, chronic kidney dis-
ase (serum creatinine >1.5 mg/dl), systemic illnesses which might
ause fatty liver, and use of drugs such as insulin sensitizing agents
metformin and glitazones) which may  improve NAFLD were the
ther exclusion criteria.
Abdominal ultrasonography (USG) was performed on all partic-
pants after coronary angiography (CAG) by a single experienced
hysician who was blind to the study population, to determine
he presence or absence of NAFLD. The presence of NAFLD was
dentiﬁed by characteristic echocardiographic patterns such as a
iffuse increase in the echogenicity of the liver when compared
ith kidney according to the conventional criteria [12,13].
MS  was deﬁned according to the US Adult Treatment Panel-III
riteria [14]. At least three of the following 5 criteria should be
resent: (1) fasting plasma glucose ≥110 mg/dl; (2) plasma triglyc-
ride (TG) level ≥150 mg/dl; (3) plasma high-density lipoprotein
HDL) level for women ≤50 mg/dl, for men  ≤40 mg/dl; (4) waist
ircumference for women >88 cm,  for men  >102 cm;  and (5) blood
ressure ≥130/85 mmHg. The estimate of IR by homeostasis model
ssessment (HOMA) was calculated with the formula: fasting
erum insulin (mIU/l) × fasting plasma glucose (mmol/l)/22.5 [15].
n individual with the HOMA index ≥2.7 was considered to have
R similar to previous studies [16].
Standard selective coronary angiography with at least 4 views
f the left coronary system and 2 views of the right coronary artery
as performed using the Judkins technique. Evaluation of collat-
ral circulation and angiographic measurements were done by two
xperienced cardiologists visually without the knowledge of clin-
cal information or laboratory data of the patients. If there was an
nconsistency between two cardiologists, angiograms were eval-
ated by another cardiologist and a consensus was  reached. The
umber of diseased vessels was identiﬁed according to the number
f the major coronary arteries having ≥70% stenosis, to analyze the
ffect of multivessel disease on coronary collateral development.
Collateral grading was performed to the vessel with coronary
rtery stenosis of >95%. In the case of more than one vessel with
igh-grade stenosis; collateral grading was carried out according
o vessel that had better collateral.
CCC was graded according to the Cohen–Rentrop method [17]:
rade 0, no ﬁlling of any collateral vessels; grade 1, ﬁlling of side
ranches of the artery to be perfused by collateral vessels without
isualization of epicardial segment; grade 2, partial ﬁlling of the
picardial artery by collateral vessels; and grade 3, as complete
lling of epicardial artery by collateral vessel. Rentrop grades of
 and 1 indicate poor CCC whereas 2 and 3 indicate good CCC.. Statistical analysis
The analysis of the results was performed using the Statistical
ackage for Social Sciences (SPSS, Chicago, IL, USA), version 16.0Fig. 1. Non-alcoholic fatty liver disease (NAFLD) in good and poor collateral groups.
software for Windows. The categorical variables were shown as
numbers of cases with percentages and the continuous variables
were shown as mean ± standard deviation. Data were tested for
normal distribution using the Kolmogorov–Smirnov test. The Stu-
dent’s t-test was  used for the univariate analysis of the continuous
variables and the 2 test for the categorical variables. Spearman
correlation coefﬁcient was  used for correlation analysis. Logis-
tic regression was  used for multivariate analysis. For multivariate
analysis, parameters having associations with collateral develop-
ment with p-values < 0.10 were entered into the analysis. In this
analysis, MS  and IR were separately entered similar to previous
studies [8]. All tests of signiﬁcance were two-tailed. Statistical sig-
niﬁcance was deﬁned as p < 0.05.
4. Results
After exclusion of patients with DM,  known CAD, previous per-
cutaneous or surgical revascularization history, and acute coronary
syndrome, 183 patients were available for the study. Among them,
151 (82.5%) were found to be eligible and 32 (17.5%) were excluded
according to the criteria mentioned before (10 had either hepati-
tis B or C antigen, 14 had chronic kidney disease, 6 were using
alcohol, and 2 were using metformin). Eighty-one (53.7%) of the
151 patients were found to have good CCC whereas 70 (46.3%)
had poor CCC. The baseline characteristics of the study population
are summarized in Table 1. Fasting plasma glucose was higher in
patients with poor CCC but this did not reach statistical signiﬁcance
(95.0 ± 10.2 mg/dl vs. 92.8 ± 9.8 mg/dl, p = 0.17). MS  and IR were
more prevalent, angina time was shorter, and number of diseased
coronary vessels > 70% was lower in patients with poor collaterals
(Table 1). Female patients tended to have poor collaterals when
compared with males (Table 1).
NAFLD was present in 98 patients (64.9% of study population).
It was  more prevalent in patients with poor CCC [58 of 70 patients
with poor CCC (82.9%) vs. 40 of 81 patients with good CCC (49.4%),
p < 0.001] (Fig. 1). There was a signiﬁcant correlation between pres-
ence of MS  and IR (r: 0.65, p < 0.001). Because of this signiﬁcant
correlation and regarding IR as a component of MS  [8],  we per-
formed logistic regression analysis involving MS and IR separately.
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Table  1
Baseline characteristics of the patients according to coronary collateral circulation.
n = 151 Poor collateral (n = 70) Good collateral (n = 81) p-value
Age (years) 60.2 ± 7.9 60.9 ± 9.7 0.63
Female sex 27 (38.6%) 16 (19.8%) 0.011
Hypertension 47 (67.1%) 55 (67.9%) 0.92
Smoking 32 (45.7%) 42 (51.9%) 0.52
Family history of CAD 15 (21.4%) 18 (22.2%) 0.90
Total  cholesterol (mg/dl) 201.3 ± 48.1 192.6 ± 43.9 0.36
LDL  (mg/dl) 127.8 ± 42.9 121.1 ± 36.5 0.30
HDL  (mg/dl) 37.8 ± 8.6 38.6 ± 9.5 0.63
Triglycerides (mg/dl) 182.1 ± 102.8 166.5 ± 79.3 0.29
Glucose (mg/dl) 95.0 ± 10.2 92.8 ± 9.8 0.17
Creatinine (mg/dl) 0.9 ± 0.3 0.9 ± 0.2 0.22
Leukocytes (/mm3) 7791 ± 1910 7578 ± 1698 0.47
Platelets (/mm3) 242,557 ± 65,382 227,379 ± 52,264 0.12
Hemoglobin (g/dl) 13.9 ± 1.6 14.3 ± 1.4 0.19
Number of diseased vessels > 70% 1.8 ± 0.9 2.2 ± 0.8 0.016
Duration of ischemic symptoms (months) 6.3 ± 7.3 9.7 ± 9.2 0.014
Metabolic syndrome 50 (71.4%) 38 (46.9%) 0.002
Increased waist circumference 39 (55.7%) 41 (50.6%) 0.53
HOMA index 2.8 ± 0.5 2.5 ± 0.6 0.008
Presence of insulin resistance 45 (64.3%) 30 (37.0%) <0.001
Angiographic information of the patients
Vessel with > 95% stenosis
Left anterior descending artery 21 (30.0%) 28 (34.6%) 0.66
Left  circumﬂex artery 16 (22.9%) 14 (17.3%)
Right  coronary artery 33 (47.1%) 39 (48.1%)
Total  occlusion of the vessel 29 (41.4%) 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; CAD, coronary artery diseas
Table 2
Odds ratios (OR) and 95% conﬁdence intervals (CI) for collateral development using
binary logistic regression.a
Predictors of coronary collateral
development
OR (95% CI) p-value
Presence of NAFLD 6.23 (2.62–14.80) <0.001
Female sex 1.89 (0.82–4.35) 0.14
Duration of ischemic symptoms 1.07 (1.02–1.12) 0.010
Presence of MS 2.28 (1.05–4.97) 0.037
Number of diseased vessels > 70% 1.80 (1.12–2.92) 0.015
NAFLD, non-alcoholic fatty liver disease; MS,  metabolic syndrome.
a In this analysis, presence of insulin resistance was entered instead of metabolic
syndrome.
Table 3
Odds ratios (OR) and 95% conﬁdence intervals (CI) for collateral development using
binary logistic regression.a
Predictors of coronary collateral
development
OR (95% CI) p-value
Presence of NAFLD 6.20 (2.61–14.75) <0.001
Female sex 1.87 (0.80–4.32) 0.14
Duration of ischemic symptoms 1.06 (1.01–1.12) 0.025
Presence of insulin resistance 2.24 (1.04–4.83) 0.040
Number of diseased vessels > 70% 1.86 (1.15–3.03) 0.012
NAFLD, non-alcoholic fatty liver disease.
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IR plays a major role in the development of NAFLD [20,21].a In this analysis, presence of insulin resistance was entered instead of metabolic
yndrome.
hen the logistic regression analysis was performed using the fac-
ors which were signiﬁcantly different between two  groups (except
or presence of IR), NAFLD was found to be independently related
o poor CCC [OR: 6.23 (2.62–14.80), p < 0.001] (Table 2). When pres-
nce of IR was entered into the multivariate analysis instead of MS,
AFLD was again independently associated with poor CCC [OR: 6.20
2.61–14.75), p < 0.001] (Table 3). Female sex was related with poor
CC in univariate analysis but this association lost its signiﬁcance
fter logistic regression analysis. Tables 2 and 3 show the results of
ogistic regression analysis.38 (46.9%) 0.50
e; HOMA, homeostasis model assessment.
When the patients were classiﬁed according to the presence or
absence of NAFLD, mean Rentrop collateral score was  signiﬁcantly
lower in patients with NAFLD (1.2 ± 1.2 vs. 2.1 ± 0.9, p < 0.001). MS
was also found to be more prevalent in patients with NAFLD [67 of
98 (68.4%) patients with NAFLD vs. 21 of 53 patients (39.6%) without
NAFLD, p < 0.001].
5. Discussion
In the present study, we have found that presence of NAFLD
is associated with poor CCC in non-diabetic patients with signiﬁ-
cant CAD. This association was independent from the other factors
affecting coronary collateral development including IR and MS.
According to our results, MS,  IR, angina time and extent of CAD
were related to CCC independent from other variables. In one study,
presence of MS  did not impair coronary collateral vessel formation
[9].  However, recent studies have revealed that MS  is associated
with poor CCC [6–8]. Our results conﬁrmed these latter studies.
Longer angina time and more severe CAD were also found to be
associated with good CCC similar to the previous studies describing
this relationship [4,5,18,19].
In univariate analysis, female sex was related to poor CCC but
after multivariate analysis, this association lost its signiﬁcance. We
thought that female patients randomly accumulated the variables
which were associated with poor CCC. In our study, fasting plasma
glucose level was  not correlated with CCC. We thought that the
absence of diabetic patients due to the selection criteria in our study
population was  the reason of it.
The prevalence of NAFLD was  high (64.9%) in our study popula-
tion. When our study population, which was  composed of patients
with severe CAD, was taken into account, this ﬁnding appeared
to be consistent with the previous studies indicating association
between the presence of NAFLD and CAD [11].NAFLD is considered as a hepatic manifestation of MS  [10]. MS
which is characterized by IR, has been found to be related to
poor collateral development [6–8]. Besides, the association of poor
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ollateral development with IR has been shown in a recent study
imilar to our ﬁndings [8]. In addition, patients with NAFLD have a
reater tendency to develop DM [22]. IR is a crucial ﬁnding in type
 DM,  and it is a well known fact that DM severely impairs collat-
ral development [3].  With these facts, we can say that presence of
AFLD may  impair coronary collateral development because of its
ssociation with IR in non-diabetic patients.
Despite the relationship found between NAFLD and MS  in our
tudy, NAFLD was independently associated with poor CCC after
ogistic regression analysis. The association between NAFLD and
oor CCC, independent from MS  and IR, raises questions about the
echanisms involved here. IR, which is related with poor CCC, is
he most pronounced ﬁnding in both MS  and NAFLD, but IR solely
annot explain all the processes involved in this association.
In a review, it has been pointed out that hepatosteatosis may  not
nly be a marker but also a mediator for CAD, independent of the
xistence of MS  [23]. The emerging evidence supports that the rela-
ionship between NAFLD and atherosclerosis mainly reﬂects the
dverse impact of the MS  phenotype, particularly IR and increased
bdominal visceral fat, possibly through its multiple secreted fac-
ors, i.e. free fatty acids, tumor necrosis factor-alpha, interleukin-6,
nd other proinﬂammatory cytokines [24,25].  These factors may
lso contribute to the poor collateral development in patients with
AFLD. Besides, decreased adiponectin concentrations in NAFLD
26,27], an anti-atherogenic cytokine released by the adipose tis-
ue, may  link this disease with poor CCC [8].  Increased C-reactive
rotein level in NAFLD [28] may  also be associated with poor col-
ateral development [29].
Interestingly, in this study, we also found no difference of the
atio between NAFLD (+) and NAFLD (−) (50.6% vs. 49.4%) patients
n the good collateral group. Monocyte chemo-attractant protein-
 (MCP-1) contributes to IR by evoking inﬂammatory reactions in
dipose tissues [30] and it is also known to contribute to the devel-
pment of NAFLD [31]. In a recent study, we have found increased
irculating CD14 (+) CD16 (−) monocytes, the main secretors of
CP-1, in patients with good collateral development [32]. Differ-
nt levels of monocyte activation and chemokine secretion such as
CP-1 in patients with NAFLD and tissue response to these inﬂam-
atory reactions may  explain why some patients can develop good
ollaterals in the presence of NAFLD. These should be investigated
y further studies.
There are some limitations in our study. Abdominal USG was
sed instead of the gold standard technique, liver biopsy, to deter-
ine hepatosteatosis, because of some ethical concerns. Using liver
istology as a standard, the positive predictive value of USG ranges
rom 77 to 96%, and the negative predictive value ranges from 65
o 87% [33–35].  Thus, potential inaccuracies by USG could negate
he statistical signiﬁcance of the ﬁndings reported.
. Conclusion
Presence of NAFLD is associated with poor CCC in non-diabetic
atients with severe CAD, independent from other variables, espe-
ially MS  and IR. Which mechanisms play a role in this relationship
s not well known and is needed to be cleared with further studies.
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